AR and chronic myelogenous leukemia, BCR-ABL1 positive: Pathway enrichment involves cytokine‐cytokine receptor pathways, including tyrosine kinase receptor activity and phosphokinase receptor and androgen receptor pathway activation; TKIs are currently the primary treatment for CML patients (Arrigoni et al., 2018).